Sales & Marketing

Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with recurrent C. difficile infections.

First once-every-two-months long-acting injectable offers sustained therapeutic concentrations for patients.

Industry leaders threaten to devote resources elsewhere.

Christopher Boerner, chief commercialization officer, set to succeed Caforio in November.

Digital and innovation leader takes issue with the current state of pharma marketing and suggests new approaches are needed.

Eli Lilly offloads innovative hypoglycemia nasal spray, Baqsimi, to Amphastar Pharmaceuticals bolstering Amphastar's diabetes portfolio.

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

Webinar Date/Time: Thu, May 18, 2023 11:00 AM EDT

The $10.8 billion deal positions Merck to acquire promising immune-disorder therapies.

J&J's Janssen Pharmaceutica NV collaborates with Pipeline Therapeutics in a $50 million licensing deal for oral MS drug PIPE-307, with potential earnings of up to $1 billion for Pipeline.

By tailoring messages, leveraging digital channels, creating personalized experiences, and fostering relationships, healthcare marketers can connect with HCPs across generations and build lasting partnerships.

It’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact.

Bankrupt Clovis Oncology offloads assets, including ovarian cancer drug Rubraca, to Swiss firm Pharma& Schweiz for over $70 million.

Regardless of engagement mode pursued, personalization is the key.

As the Biden Administration transitions Covid-19-related costs to public and private markets, Moderna is increasing its vaccine price from $26 to $130 per dose.

Eli Lilly debuts its first Mounjaro TV commercial amid high demand for the diabetes injection, which also shows promise in weight loss applications and outperformed rivals Ozempic and Wegovy in clinical trials.

Fingerpaint Group further enforces its commitment to the space, marking its second market access acquisition in three years.

How to build a modular content system to optimize content creation and delivery, Using Al-powered engines that know your HCP's viewing behavior, using discomfort as an advantage and much more.

How media consumption is evolving and modifying digital and social strategies to best capture the behavioral changes of HCPs towards digital platforms.

EVERSANA honored for innovative use of artificial intelligence in video production — enhancing educational content development for the life science industry.

The combined company is expected to deliver a superior health care experience and drive better outcomes.

Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?

Indegene's Jitesh Sah, Vice President, Analytics and Vikas Mahajan, Sr. Director, Data & Analytics chat with senior editor Fran Pollaro about the challenge of data drift.

TikTok is facing a potential ban in the US over national security concerns and advertisers are avoiding the platform or putting together contingency plans.

The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.

Pharma firm is seeking buyers for front-of-eye portfolio and assets include Xiidra, which had $487 million of sales in 2022.

Pending FDA approval, agreement expected to support once-daily stimulant medication.

Havas Health & You to navigate complexities around value, access, pricing, and reimbursement.

Pfizer will pay pay $229 a share in cash for the cancer specialist.

Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.